The 2014–2015 influenza season was very active in British Columbia and throughout Canada. Widespread influenza activity, predominantly A(H3N2), was observed throughout most regions of the province. The BC Centre for Disease Control’s Influenza Surveillance Reports indicated that the proportion of visits to sentinel physicians and to the BC Children’s Hospital emergency room for influenza-like illness were well above average seasonal rates. One of the reasons suggested for this increase was the mismatch between influenza vaccine serotypes and circulating serotypes. With the rise in suspected or confirmed influenza cases, many clinicians have faced questions regarding the ideal management of influenza infection, particularly in the higher-risk populations of young children and pregnant women since influenza virus infection in these populations can result in significant morbidity and mortality.

Immunization is the main preventive measure against influenza viruses. However, for certain patients who develop infection with influenza A or B, oseltamivir is an important treatment option.

Karen Ng, BScPharm, PharmD, BCPS, Vanessa Paquette, BScPharm, PharmD, Kristopher T. Kang, MD, Soren Gantt, MD, PhD, FRCPC, Ashley Roberts, MD, FRCPC

Dr Ng is a pediatric antimicrobial stewardship clinical pharmacy specialist at BC Children’s Hospital. Dr Paquette is a clinical pharmacy specialist at BC Women’s Hospital and Health Centre. Dr Kang is an academic general pediatrician at BC Children’s Hospital. Dr Gantt is a pediatric infectious diseases consultant at BC Children’s Hospital and directs a virology laboratory at the Child and Family Research Institute. Dr Roberts is a pediatric infectious diseases specialist at BC Children’s Hospital and is the medical director of the antimicrobial stewardship program at the Provincial Health Services Authority.

This article has been peer reviewed.

Management of influenza infection in children and pregnant women in BC, an update

Immunization is the main preventive measure against influenza viruses. However, for certain patients who develop infection with influenza A or B, oseltamivir is an important treatment option.

Karen Ng, BScPharm, PharmD, BCPS, Vanessa Paquette, BScPharm, PharmD, Kristopher T. Kang, MD, Soren Gantt, MD, PhD, FRCPC, Ashley Roberts, MD, FRCPC

Dr Ng is a pediatric antimicrobial stewardship clinical pharmacy specialist at BC Children’s Hospital. Dr Paquette is a clinical pharmacy specialist at BC Women’s Hospital and Health Centre. Dr Kang is an academic general pediatrician at BC Children’s Hospital. Dr Gantt is a pediatric infectious diseases consultant at BC Children’s Hospital and directs a virology laboratory at the Child and Family Research Institute. Dr Roberts is a pediatric infectious diseases specialist at BC Children’s Hospital and is the medical director of the antimicrobial stewardship program at the Provincial Health Services Authority.

This article has been peer reviewed.
est benefits of oseltamivir are seen if treatment is initiated within 2 days of symptom onset, though evidence also supports the efficacy of treatment that is started later.26 Although its overall benefits are modest, oseltamivir is the most active antiviral available for influenza and is the standard of care for the treatment of influenza among high-risk or severely ill patients.2,19,20

Oseltamivir for treatment of influenza in children

Much less evidence exists to guide the management of children with influenza compared with adults.20 The hospitalization rate and risk of adverse events related to influenza infection is higher in children under 5 years of age, and especially in those under 2 years of age, compared with older children. Children with certain chronic conditions or compromised immunity are also at greater risk when they contract influenza infection.19

A Cochrane review of 2356 children, of which 1255 had laboratory-confirmed influenza, also found that oseltamivir treatment provided a modest benefit in the duration of illness and incidence of acute otitis media but increased nausea and vomiting.4 Benefits of oseltamivir may be more pronounced in hospitalized children and oseltamivir may decrease the length of hospital stays,21 along with potentially preventing hospitalization in high-risk patients.22 The Canadian Paediatric Society, Centers for Disease Control and Prevention, and American Academy of Pediatrics all recommend the empiric use of oseltamivir to manage influenza illness, particularly in hospitalized children and those at high risk for complications.20,23,24

No neuraminidase inhibitors are approved for children younger than 1 year of age in Canada, but oseltamivir was approved temporarily for use in this age group based on a favorable risk-to-benefit ratio during the 2009 H1N1 pandemic. Evidence and dosing studies exist for infants younger than 1 year of age,25 and the Canadian Paediatric Society guidelines continue to recommend oseltamivir for this age group.20

Oseltamivir for treatment of influenza in pregnant women

Pregnant women and women up to 4 weeks postpartum are also at high risk for influenza-related complications.2,26 Increased severity of illness, increased hospitalizations, and increased mortality have been observed, particularly in women with influenza in their third trimester.26,27 Influenza in pregnancy has also been associated with effects on the fetus, including congenital abnormalities, low birth weight, preterm delivery, and fetal death.2,28-30

Oseltamivir is considered the antiviral medication of choice for pregnant women for the treatment of influenza.2,24,31 Results from studies of pregnant women during the H1N1 pandemic in 2009 suggest that early treatment with oseltamivir may reduce ICU admissions and mortality.6,7 Current data do not suggest any increased risk to the developing fetus if oseltamivir is taken during pregnancy.32 Treatment guidelines from the Association of Medical Microbiology and Infectious Disease Canada, Centers for Disease Control and Prevention, and the Infectious Diseases Society of America all recommend oseltamivir use for the treatment of suspected and confirmed influenza in the pregnant population.2,24,31

Local guidance for oseltamivir use in children and pregnant women

Despite being the mainstay of influenza treatment, oseltamivir has been found to be underused in BC, especially in the highest-risk age groups.32 To promote rational use of oseltamivir the Infectious Diseases and Antimicrobial Stewardship Group from BC Children’s and Women’s Hospitals produced two treatment algorithms adapted from available guidelines to optimize oseltamivir use in children and pregnant women with suspected or confirmed influenza infection. Because of the availability of rapid influenza diagnostic testing in BC Children’s and Women’s Hospitals, the influenza protocol was designed to use oseltamivir only in confirmed influenza-positive patients with risk factors for complications, limiting empiric oseltamivir use to pregnant women and critically ill patients or as necessary according to clinical judgment. When testing with nasopharyngeal wash specimens is not feasible or rapid tests are not available, empiric therapy should be initiated in all high-risk patients with influenza-like illness without waiting for laboratory results to minimize treatment delay and maximize efficacy.

The BC Children’s Hospital pediatric oseltamivir treatment algorithm (Figure 1) is available at http://bcchcm.medworxx.com/Site_Published/bcc/document_render.aspx?documentRender.Id=16093.

The BC Women’s Hospital oseltamivir treatment algorithm for pregnant women (Figure 2) is available at http://bcchcm.medworxx.com/Site_Published/bcw/document_render.aspx?documentRender.Id=16922.

Competing interests

None declared. No author has any association with the manufacturers of Tamiflu.

References

BCCH Algorithm For Oseltamivir Treatment of Influenza in Children and Youth (2 weeks to 18 years of age)

Patients with influenza-like-illness (ILI) presenting to the Emergency Department

ILI is characterized by the abrupt onset of constitutional and respiratory signs and symptoms (e.g., fever, myalgia, headache, malaise, nonproductive cough, sore throat, and rinitis)

Admitted (Inpatient management)

Non-admitted (Outpatient management)

Presence of risk factors for influenza complications or household contact of confirmed influenza-positive patient?

No

Yes, then consider

Start empiric oseltamivir

Influenza positive

Influenza negative

Await NPW results

Discontinue oseltamivir based on clinical judgment

Continue oseltamivir therapy

Oseltamivir treatment not indicated

Influenza negative

Influenza positive

Start oseltamivir

Non-critical care ward

Admitted to PICU

Start empiric oseltamivir

Influenza positive

Influenza negative

Oseltamivir treatment not indicated

Presence of risk factors for influenza complications or household contact of confirmed influenza-positive patient, and within 48 hours of symptom-onset?

No

Yes, then consider

Send Home

NPW

*Risk Factors for Influenza Complications

• Asthma or other chronic pulmonary disease
• Cardiovascular disease
• Malignancy
• Immunosuppression or immunodeficiency
• First Nations, Inuit and Métis children and youth
• Diabetes mellitus and other metabolic diseases
• Hemoglobinopathies such as sickle cell disease
• Neurological disease or neurodevelopmental disorders that compromise handling of respiratory secretions
• Chronic renal insufficiency
• Chronic liver disease
• Children or youth who reside in homes or other chronic care facilities
• Individuals <18 years of age who are on chronic acetylsalicylic acid therapy
• Obesity with BMI ≥40 kg/m², OR a BMI ≥3 z-scores above the mean for age and gender

Dose interval and duration adjustment in renal impairment:

Patients with GFR <30 mL/min: once daily x 5 days

Patients on PD/HD: once daily x 2 days

Osimetamivir dosing for treatment of influenza:

Children <12 months: 3 mg/kg/dose PO twice daily x 5 days

Children ≥12 months to <13 years:

• ≤15 kg: 30 mg PO twice daily x 5 days

• >15 kg to ≤23 kg: 45 mg PO twice daily x 5 days

• >23 kg to ≤40 kg: 60 mg PO twice daily x 5 days

• >40 kg: 75 mg PO twice daily x 5 days

• Adolescents ≥13 years and adults:

• 75 mg PO twice daily x 5 days

Note:

• Greatest benefit is when oseltamivir is started within 48 hours of influenza illness onset, but may still be beneficial when administered >48 hours.
• Confirmation of a negative NPW requires a negative PCR for Influenza virus A and B.
• NPW = Nasopharyngeal Wash

References:

BCWH Algorithm For Oseltamivir Treatment of Influenza in Pregnant Women*

Patients with influenza-like-illness (ILI)

*Pregnant women and women up to 4 weeks postpartum are considered at high risk for influenza related complications. Increased hospitalization rates, stillbirths, premature deliveries and increased infant and maternal mortality have been observed particularly in women who have influenza in their third trimester.

ILI is characterized by:
- Fever and cough
- Fever and gastrointestinal symptoms (nausea, vomiting, diarrhea)
- Contact with anyone with flu like symptoms in the last 7 days
- Any of the following: muscle aches, joint pains, sore throat, extreme fatigue or weakness

**Note:**
- Oseltamivir may reduce the duration of hospitalization, ICU admissions and mortality in hospitalized patients with influenza and reduce lower respiratory tract complications in outpatients.
- Greatest benefit is when oseltamivir is started within 48 hours of influenza illness onset, but may still be beneficial when administered >48 hours.
- #Confirmation of a negative FLOQSwab/NPW requires a negative PCR for influenza virus A and B. VIRAP = Viral rapid testing program
- +FLOQSwab = flocked nasopharyngeal swab; NPW = nasopharyngeal wash

Start empiric oseltamivir

Influenza negative by VIRAP

Await PCR results

Influenza positive by VIRAP

Continue oseltamivir

Discontinue oseltamivir

Oseltamivir dosing for treatment of influenza:
- All adults (including pregnant women): 75 mg po BID x 5 days
- Dose interval adjustment in renal impairment:
  - Patients with GFR 31 to 60 mL/min: 75 mg po once daily x 5 days OR 30 mg po BID x 5 days
  - Patients with GFR < 30 mL/min: 30 mg po once daily x 5 days

To order antiviral therapy please refer to pre-printed orders: Treatment and Monitoring of Women with Influenza (WW.13.03C)

Please refer to Fetal Maternal Newborn Policy Influenza Virus: Managing Women Presenting to BCW (WW.13.03A) for further details.

References:

January 2015

Figure 2. The BC Women’s Hospital oseltamivir treatment algorithm for pregnant women

Continued on page 406
Continued from page 405


